Stay updated with breaking news from Small Anim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDASAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or
91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia®-CA1 over timeCanalevia-CA1, Jaguar Health's FDA Conditionally
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDAIn December 2022, FDA increased the maximum number of dogs that can be treated annually with a
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar